Literature DB >> 17449457

The 6-hydroxydopamine model of Parkinson's disease.

Nicola Simola1, Micaela Morelli, Anna R Carta.   

Abstract

The neurotoxin 6-hydroxydopamine (6-OHDA) continues to constitute a valuable topical tool used chiefly in modeling Parkinson's disease in the rat. The classical method of intracerebral infusion of 6-OHDA involving a massive destruction of nigrostriatal dopaminergic neurons, is largely used to investigate motor and biochemical dysfunctions in Parkinson's disease. Subsequently, more subtle models of partial dopaminergic degeneration have been developed with the aim of revealing finer motor deficits. The present review will examine the main features of 6-OHDA models, namely the mechanisms of neurotoxin-induced neurodegeneration as well as several behavioural deficits and motor dysfunctions, including the priming model, modeled by this means. An overview of the most recent morphological and biochemical findings obtained with the 6-OHDA model will also be provided, particular attention being focused on the newly investigated intracellular mechanisms at the striatal level (e.g., A(2A) and NMDA receptors, PKA, CaMKII, ERK kinases, as well as immediate early genes, GAD67 and peptides). Thanks to studies performed in the 6-OHDA model, all these mechanisms have now been hypothesised to represent the site of pathological dysfunction at cellular level in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17449457     DOI: 10.1007/bf03033565

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  153 in total

1.  Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines.

Authors:  T F Freund; J F Powell; A D Smith
Journal:  Neuroscience       Date:  1984-12       Impact factor: 3.590

2.  Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane.

Authors:  A W Dunah; D G Standaert
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

3.  Behavioural sensitization in 6-hydroxydopamine-lesioned rats is related to compositional changes of the AP-1 transcription factor: evidence for induction of FosB- and JunD-related proteins.

Authors:  D Vallone; M T Pellecchia; M Morelli; P Verde; G DiChiara; P Barone
Journal:  Brain Res Mol Brain Res       Date:  1997-12-15

Review 4.  Applications of the Morris water maze in the study of learning and memory.

Authors:  R D'Hooge; P P De Deyn
Journal:  Brain Res Brain Res Rev       Date:  2001-08

5.  Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: motor behavior and monoamine alterations at adult stage.

Authors:  J Luthman; A Fredriksson; E Sundström; G Jonsson; T Archer
Journal:  Behav Brain Res       Date:  1989-07-01       Impact factor: 3.332

6.  Testing forelimb placing "across the midline" reveals distinct, lesion-dependent patterns of recovery in rats.

Authors:  Martin T Woodlee; Aloysha M Asseo-García; Xiurong Zhao; Shi-Jie Liu; Theresa A Jones; Timothy Schallert
Journal:  Exp Neurol       Date:  2005-02       Impact factor: 5.330

7.  Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.

Authors:  M Olsson; G Nikkhah; C Bentlage; A Björklund
Journal:  J Neurosci       Date:  1995-05       Impact factor: 6.167

8.  Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.

Authors:  G R Breese; A A Baumeister; T J McCown; S G Emerick; G D Frye; K Crotty; R A Mueller
Journal:  J Pharmacol Exp Ther       Date:  1984-11       Impact factor: 4.030

9.  Ventrolateral striatal dopamine depletions impair feeding and food handling in rats.

Authors:  J D Salamone; K Mahan; S Rogers
Journal:  Pharmacol Biochem Behav       Date:  1993-03       Impact factor: 3.533

10.  Sustained extracellular signal-regulated kinase 1/2 phosphorylation in neonate 6-hydroxydopamine-lesioned rats after repeated D1-dopamine receptor agonist administration: implications for NMDA receptor involvement.

Authors:  Sophia T Papadeas; Bonita L Blake; Darin J Knapp; George R Breese
Journal:  J Neurosci       Date:  2004-06-30       Impact factor: 6.167

View more
  119 in total

1.  Brilliant Blue G, But Not Fenofibrate, Treatment Reverts Hemiparkinsonian Behavior and Restores Dopamine Levels in an Animal Model of Parkinson's Disease.

Authors:  Enéas G Ferrazoli; Héllio D N de Souza; Isis C Nascimento; Ágatha Oliveira-Giacomelli; Telma T Schwindt; Luiz R Britto; Henning Ulrich
Journal:  Cell Transplant       Date:  2017-04-13       Impact factor: 4.064

Review 2.  Aminochrome as a preclinical experimental model to study degeneration of dopaminergic neurons in Parkinson's disease.

Authors:  Irmgard Paris; Sergio Cardenas; Jorge Lozano; Carolina Perez-Pastene; Rebecca Graumann; Alejandra Riveros; Pablo Caviedes; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2007-09       Impact factor: 3.911

3.  6-OHDA induces cycle reentry and apoptosis of PC12 cells through activation of ERK1/2 signaling pathway.

Authors:  Zhentao Zhang; Tao Wang; Xuebing Cao; Shenggang Sun; Lan Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-02-18

4.  The role of exercise in facilitating basal ganglia function in Parkinson's disease.

Authors:  Giselle M Petzinger; Beth E Fisher; Garnik Akopian; Daniel P Holschneider; Ruth Wood; John P Walsh; Brett Lund; Charles Meshul; Marta Vuckovic; Michael W Jakowec
Journal:  Neurodegener Dis Manag       Date:  2011-04-01

5.  Spatial distribution of 5-hydroxymethyl cytosine in rat brain and temporal distribution in striatum.

Authors:  Tingting Zheng; Qing Lv; Xiaoguang Lei; Xinzhen Yin; Baorong Zhang
Journal:  Neurochem Res       Date:  2015-02-03       Impact factor: 3.996

Review 6.  A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists.

Authors:  Annalisa Pinna; Micaela Morelli
Journal:  Neurotox Res       Date:  2013-12-10       Impact factor: 3.911

7.  Neuroprotective Activities of Spirulina platensis in the 6-OHDA Model of Parkinson's Disease Are Related to Its Anti-Inflammatory Effects.

Authors:  Francisco Arnaldo Viana Lima; Ivan Pinheiro Joventino; Francisca Pinheiro Joventino; Aline Cordeiro de Almeida; Kelly Rose Tavares Neves; Marta Regina do Carmo; Luzia Kalyne Almeida Moreira Leal; Geanne Matos de Andrade; Glauce Socorro de Barros Viana
Journal:  Neurochem Res       Date:  2017-08-31       Impact factor: 3.996

Review 8.  Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.

Authors:  Kelly M Lohr; Shababa T Masoud; Ali Salahpour; Gary W Miller
Journal:  Eur J Neurosci       Date:  2016-09-02       Impact factor: 3.386

Review 9.  Antioxidants in central nervous system diseases: preclinical promise and translational challenges.

Authors:  Chandrashekhar D Kamat; Sunyana Gadal; Molina Mhatre; Kelly S Williamson; Quentin N Pye; Kenneth Hensley
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

10.  Intrastriatal 6-OHDA lesion differentially affects dopaminergic neurons in the ventral tegmental area of prenatally stressed rats.

Authors:  Carlos J Baier; María Eugenia Pallarés; Ezequiela Adrover; María R Katunar; Rita Raisman-Vozari; Marta C Antonelli
Journal:  Neurotox Res       Date:  2014-06-17       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.